Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients With Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies.

Abstract

HER2 overexpression occurs in various subtypes of salivary gland cancers (SGCs) and can be associated with treatment challenges and poor clinical outcomes. Zanidatamab is a dual HER2-targeted, bispecific antibody that has demonstrated antitumor activity across multiple HER2-positive tumor types. This combined analysis aimed to assess the efficacy and safety of zanidatamab in HER2-positive SGC. Adult patients with previously treated, unresectable locally advanced or metastatic HER2-positive SGC were enrolled in 3 early-phase trials of zanidatamab: a first-in-human phase I study (NCT02892123), a phase I study of patients in Japan (JRCT2031210161), and a phase Ib/II study evaluating zanidatamab plus evorpacept, a high-affinity CD47 inhibitor (NCT05027139). Confirmed objective response rate (cORR) and progression-free survival (PFS) were measured in each study. Outcomes with zanidatamab monotherapy were pooled for summary analysis. Ten patients with HER2-positive SGC were enrolled across trials; 6 patients were previously treated with HER2-targeted therapy. Among patients who received zanidatamab monotherapy (n = 9), 7 experienced zanidatamab-related adverse events (all grade 1/2), the most common being diarrhea and infusion-related reactions. The cORR (95% CI) was 44% (14%-79%), the median (95% CI) PFS was 10.1 (3.8-not estimable) months, and the median (range) duration of response was not reached (9.4-42.3+) months. All patients experienced a reduction in tumor size. One patient who received zanidatamab plus evorpacept experienced a confirmed partial response and 18.4 months of PFS. Although the sample size is small, these findings support the clinical benefit of zanidatamab treatment for HER2-positive SGC.